China National Pharmaceutical Group Corporation

Chengdu, China

China National Pharmaceutical Group Corporation

Chengdu, China
Time filter
Source Type

Wang Z.-Y.,Anhui Anke yuliangqing Pharmaceutical Co. | Wang J.,China National Medicines Guorui Pharmaceutical Co. | Zhu Z.-J.,China National Pharmaceutical Group Co. | Xu D.-B.,China National Medicines Guorui Pharmaceutical Co.
Chinese Journal of New Drugs | Year: 2017

Objective: To analyze the general patterns and characteristics of the adverse drug reactions (ADRs) induced by potassium sodium dehydroandroandrographolide succinate for injection, and provide references for the clinical medication. Methods: ADRs of potassium sodium dehydroandroandrographolide succinate for injection reported by medical science journals were collected from China National Knowledge Infrastructure (CNKI) and Chinese Scientific Journals Database (VIP) from 2006 to 2016, and ADRs reported in National Adverse Drug Reaction Monitoring Center in 2015, and analyzed statistically. Results: A total of 653 ADRs were identified and included in the analysis. Patients at the age of 0 to 17 years showed the highest incidence (n=398, 61%). ADRs of potassium sodium dehydroandroandrographolide succinate for injection frequently occurred during 30 minutes after medication (n=510, 78%). The main ADRs were damage of skin and its appendages and systemic damage (n=358, 51%). The vast majority results of ADRs were cured and improved (n=605, 92.6%), no death report was found. Conclusion: Clinicians should reasonably use potassium sodium dehydroandroandrographolide succinate for injection and tightly monitor its use to reduce the incidences of ADRs. © 2017, Chinese Journal of New Drugs Co. Ltd. All right reserved.

Zou K.,China National Pharmaceutical Group Corporation | Zhang Q.,China National Pharmaceutical Group Corporation | Xia Y.,China National Pharmaceutical Group Corporation
Chinese Journal of Antibiotics | Year: 2011

Objective Response surface analysis (RSA) was applied to optimize the culture medium for improving the production of teicoplanin. Methods Actinoplanes teichomyceticus SIIA 04-7-34 was starting stain. Single-factor designs were used to determine the ranges of value of each related factor which may effect the production of teicoplanin. Then Plackett-Burman factorial design was carried out, to evaluate the effect of different culture conditions on the production of teicoplanin. Results Thirteen variables were examined for their significance on teicoplanin production. Among those variables, glucose, vaccination age and KH2PO4 were found to be the most significant variables that encourage teicoplanin production. Conclusion The experimental results show that teicoplanin fementation production was increased by 23.3% compared with that obtained at the unoptimized conditions. The actual value was basically consistent with the predicted value.

Jiang X.-L.,China National Pharmaceutical Group Corporation | Cui Y.-B.,China National Pharmaceutical Group Corporation | Cao S.-H.,China National Pharmaceutical Group Corporation
Chinese Journal of Antibiotics | Year: 2011

This article has reviewed progress in research on quinolone antibacterials in recent years,which consisted of newly launched products, agents in clinical trials and future development of this kind of drugs.It focused on some clinical promising candidates. Among these drugs, delafloxacin would be the most potential candidate. Moreover it introduced new fields of the future development, including modifying side chain, quinolone-like compounds, antibacterial quinolone hybrids and anti-TB quinolone-drug conjugates.

Xue Y.,China National Pharmaceutical Group Corporation | Chen Y.-Y.,China National Pharmaceutical Group Corporation
Chinese Journal of Antibiotics | Year: 2011

Cephalosporins antibiotics play an extremely important role in clinical use. This article summarized the history and the main trend of cephalosporins in the domestic and foreign markets, through retrieving massively domestic and foreign literature. The hot spots of cephalosporins in recent years and the development in future are also discussed. The research have shown that the antibiotics of cephalosporins have broad prospect in the whole industry of antibiotics.

OMER, ISRAEL--(Marketwired - Feb 16, 2017) - Medigus Ltd. ( : MDGS) ( : MDGS), a medical device company developing minimally invasive endosurgical tools and a leader in direct visualization technology, today announced that the China Food and Drug Administration, or CFDA, has approved the commencement of the first multi-center MUSE™ Clinical Study in China. Approval to start the multi-center MUSE™ clinical study was received after the CFDA reviewed the ethics committees' approval and agreements were in place with each center. Under Principal Investigator, Yunsheng Yang, Director of Gastroenterology Department Clinical center at 301 Hospital and chairman of Chinese Society of Gastroenterology, The General Hospital of People's Liberation Army in Beijing, the clinical study of approximately 62 patients, will take place at 5 centers across China: Procedures are expected to start in March and carry on through 2017, with results being reported to the CFDA in 2018 as part of the submission for clearance to sell MUSE™ in China. "With the approval of the clinical study, we are now a step closer to the first-in-man MUSE™ procedure in China," said Chris Rowland, CEO of Medigus. "We will continue to work closely with our partners to expand the use of MUSE worldwide." As Medigus works to obtain CFDA approval for MUSE™, the company is in progressive negotiations pertaining to an addendum to its current agreement with Shanghai Golden-Grand Medical Instruments Co. Ltd., or Golden, under which Medigus intends to provide Golden an aggregate sum of US$175,000 to be used in financing of the efforts. Golden is a Chinese company specializing in the distribution of medical devices in the gastroenterology field, which was appointed as a sub-distributor by Sinopharm (China National Pharmaceutical Group Corporation) - Medigus' exclusive distributor of MUSETM in China. In regards to the agreement addendum, the amount is expected to be transferred to Golden in two tranches. The anticipated timeline is as follows, the first tranche, in the amount of US$ 100,000, transferred to Golden within ten workdays from signing the addendum and the remaining US$ 75,000 be transferred to Golden within ten workdays from the date of completion of the first human procedure using the MUSE™. The MUSE system is a single-use flexible transoral stapler that merges the latest advancements in microvisual, ultrasonic and surgical stapling. The device comes equipped with an ultrasonic sight and range finder and a micro ScoutCam™ CMOS camera, which enables a single physician to perform an incisionless transoral fundoplication -- the procedure intended to treat the anatomical cause of gastroesophageal reflux disease (GERD). For more information about the clinical study or to determine if you are eligible for the trial, patients can directly contact participating medical centers. About Medigus Medigus is a medical device company specializing in developing minimally invasive endosurgical tools and highly innovative imaging solutions. They are the pioneer developer of the MUSE™ system, an FDA cleared and CE marked endoscopic device to perform Transoral Fundoplication (TF) for the treatment of GERD (gastroesophageal reflux disease), one of the most common chronic conditions in the world. In 2016, the CMS established the Category I CPT® Code of 43210 for TF procedures, such as the ones performed with MUSE, which establishes reimbursement values for physicians and hospitals. MUSE is gaining adoption in key markets around the world -- it is available in world-leading healthcare institutions in the U.S., Europe and Israel. Medigus is also in the process of obtaining regulatory clearance in China. Medigus is traded on the Nasdaq Capital Market and the TASE (Tel-Aviv Stock Exchange). To learn more about the company's advanced technology, please visit or This press release may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions and expectations of the company's management and its knowledge of the relevant market. The company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. These forward-looking statements represent Medigus' expectations or beliefs concerning future events, and it is possible that the results described in this news release will not be achieved. By their nature, Forward-Looking Statements involve known and unknown risks, uncertainties and other factors which may cause future results of the company's activity to differ significantly from the content and implications of such statements. Other risk factors affecting the company are discussed in detail in the Company's filings with the Securities and Exchange Commission. Forward-Looking Statements are pertinent only as of the date on which they are made, and the company undertakes no obligation to update or revise any Forward-Looking Statements, whether as a result of new information, future developments or otherwise. Neither the company nor its shareholders, officers and employees, shall be liable for any action and the results of any action taken by any person based on the information contained herein, including without limitation the purchase or sale of company securities. Nothing in this press release should be deemed to be medical or other advice of any kind.

He H.,Centers for Disease Control and Prevention | Chen E.,Centers for Disease Control and Prevention | Chen H.,China National Pharmaceutical Group Corporation | Wang Z.,Centers for Disease Control and Prevention | And 6 more authors.
Vaccine | Year: 2014

Two doses of measles-mumps-rubella (MMR) strategy has been recommended by World Health Organization and is also widely adopted in many countries. In order to provide the evidence for perfecting the immunization strategy of MMR, this study evaluated the safety and immunogenicity of MMR with different two-dose schedule in infants. 280 participants were enrolled and randomly allocated to Group 1 (first dose at 8 months) or Group 2 (first dose at 12 months), and both groups administered the second dose at 10 months later. Solicited local and general symptoms after each vaccination with MMR were mild and infrequent in all participants of two groups. After administration of the first dose of MMR, seropositive rates were 100% in both groups for measles, 89.3% in Group 1 and 87.1% in Group 2 for mumps (P= 0.578), 92.0% in Group 1 and 92.9% in Group 2 (P= 0.393). The seropositive rates of mumps decreased significantly (from >86% to <65%) both in two groups (P<. 0.001) 10 months after the first dose of MMR, but no significant change was found in measles and rubella. All children get the positive titer for three vaccines in two groups after given the second dose MMR, higher seroconversion rate was found for mumps both in two groups (71.7% vs 77.2%, P= 0.370). In conclusion, this study indicated that the MMR was well tolerated and immunogenic against measles, mumps and rubella with schedule of first dose both at 8 months and 12 months age. Our findings strongly supported that two doses of MMR can be introduced by replacing the first dose of MR in current EPI with MMR at 8 months age and the second dose at 18 months in China. © 2014 Elsevier Ltd.

Ye L.-J.,Sichuan University | Ye L.-J.,China National Pharmaceutical Group Corporation | Wang L.,Sichuan University | Wang L.,China National Pharmaceutical Group Corporation | And 2 more authors.
Biotechnology Letters | Year: 2012

α-Amino acid ester hydrolases (AEHs) catalyze the synthesis of β-lactam antibiotics containing an α-amino group with decreased activity toward antibiotics with a p-hydroxyl group. The AEH gene from Xanthomonas rubrillineans was cloned and expressed in Escherichia coli. Based on the crystal structure of the AEH and cefprozil complex, 13 residues not directly involved in substrate recognition were mutated individually. The resulting ~1,300 mutants were screened for activity using cefprozil as a model product based on spectrophotometric assay in a 96-well format. Mutants with improved cefprozil synthetic activity revealed the particular importance of positions 87, 131 and 175 for specificity. The mutant V131S with the highest initial rates of synthesis toward three p-hydroxyl cephalosporins showed 23 %, 17 % and 64 % increase in maximum product accumulation of cefadroxil, cefprozil and cefatrizine, respectively. © 2012 Springer Science+Business Media B.V.

Chen M.,Southwest University of Science and Technology | Tang Y.L.,Southwest University of Science and Technology | Ao J.,Southwest University of Science and Technology | Ao J.,China National Pharmaceutical Group Corporation | Wang D.,Southwest University of Science and Technology
Russian Journal of Plant Physiology | Year: 2012

The threat of environmental strontium pollution led to an increased interest to elucidating the mechanisms of this metal toxicity in the organism. To investigate strontium effects on vital photosynthesis characteristics, three-leaf stage oilseed rape seedlings (Brassica napus L., cv. Mianyou No. 15), raised in the hydroponic culture, were provided with a nutrient solution containing 0, 10, 20, and 40 mM SrCl 2. Strontium uptake and distribution in oilseed rape plants and its effect on various aspects of photosynthesis were investigated after 0, 7, 14, and 21 days of strontium treatment. Oilseed rape seedlings demonstrated a strong ability of strontium accumulation. Strontium absorbed by roots was primarily transferred to leaves and accumulated there. The leaf photosynthetic oxygen evolution rate, chlorophyll content, and Rubisco (EC 4. 1. 3. 9) and phosphoenolpyruvate carboxylase (PEPCase; EC 4. 1. 1. 31) activities declined progressively with increasing concentration of applied strontium and also with increasing the duration of exposure time. These results indicate that strontium accumulated in leaves damaged various processes of photosynthesis, such as energy absorption, energy transfer, and photosynthetic carbon assimilation. © 2012 Pleiades Publishing, Ltd.

Zhou Y.-F.,China National Pharmaceutical Group Corporation | Chu Y.-W.,China National Pharmaceutical Group Corporation | Wang X.-R.,China National Pharmaceutical Group Corporation
Chinese Journal of New Drugs | Year: 2012

Objective: To develop a HPLC-ELSD method for impurity test of miglitol and 1-deoxynojirimycin (1-DNJ). Methods: The impurities were determined by a standard curve method. Inertsil Amide column (250 mm×4.6 mm, 5 μm) was used as the HPLC column. The separation was performed using a mixture of acetonitrile and distilles water (75:25, containing 15 mmol·L -1 ammonium acetate, pH 5.5). The flow rate was adjusted at 1.2 mL·min -1, column temperature is 35°C. One of split eluents was sent to an Alltech ELSD 2000 evaporative light scattering detector. The temperature of the drift tube was set at 90°C, and the flow of gas at 2.9 L·min -1. Results: A good log-linear correlation was found between the peak areas and concentrations of miglitol and 1-deoxynojirimycin (0.02~5.05 mg·mL -1). The correlation coefficients were 0.9985 and 0.998 9 for miglitol and 1-deoxynojirimycin, respectively. The quantitative limit and detectable limit were 1 and 0.4 μg, respectively. The two compounds had good reproducibility in the chromatographic conditions. When the precision was equal to 6, RSDs were 1.5% and 1.0%. Conclusion: The improved HPLC-ELSD method is effective, fast and simple. The results are reliable and accurate, so it can be used for impurity test of miglitol and 1-deoxynojirimycin.

Ma S.,China National Pharmaceutical Group Corporation | Jia J.-Y.,China National Pharmaceutical Group Corporation | Yuan H.,China National Pharmaceutical Group Corporation | Cao S.-H.,China National Pharmaceutical Group Corporation
Chinese Journal of New Drugs | Year: 2013

Objective: To synthesize telavancin and improve the synthetic process. Methods: Decylamine and glyoxal 1, 1-dimethylacetal as the starting materials were reacted by reductive amination. 9-Fluorenylmethyl chloroformate was used to protect imino group, and hydrochloric acid hydrolyzed the acetal to afford N-Fmoc-decylaminoethanal (9). Vancomycin hydrochloride was reacted with compound 9 by reductive amination, and then the 9-fluorenylmethoxycarbonyl group was deprotected, followed by reaction with aminomethylphosphonic acid by Mannich reaction to provide the target compound. Results: The total yield of the synthetic route from vancomycin hydrochloride was 40.97%. The structure of telavancin was confirmed by MS and 1H-NMR. Conclusion: This optimized synthetic route is easy to operate, the cost is lower and the yield is higher.

Loading China National Pharmaceutical Group Corporation collaborators
Loading China National Pharmaceutical Group Corporation collaborators